GLUE · Monte Rosa Therapeutics Inc
United States · RS rating 7 · As of 2026-10-14
| Price | 9.84 USD |
|---|---|
| 1-day change | -0.5% |
| RS rating (overall / 1M / 3M / 12M) | 7 / 9 / 4 / 37 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 24 / 5 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -60.6% |
| Sales growth Q/Q | -78.2% |
| Distance from 52-week high | +61.1% |
| Market cap (USD) | $1.6B |